Acute cutaneous necrosis is characterised by a wide range of aetiologies and is associated with significant morbidity and mortality, warranting complex considerations in management. Early recognition is imperative in diagnosis and management of sudden gangrenous changes in the skin. This review discusses major causes of cutaneous necrosis, examines the need for early assessment, and integrates techniques related to diagnosis and management. The literature, available via PubMed, on acute cutaneous necrotic syndromes was reviewed to summarise causes and synthesise appropriate treatment strategies to create a clinician’s guide in the early diagnosis and management of acute cutaneous necrosis. Highlighted in this article are key features associated with common causes of acute cutaneous necrosis: warfarin-induced skin necrosis, heparin-induced skin necrosis, calciphylaxis, pyoderma gangrenosum, embolic phenomena, purpura fulminans, brown recluse spider bite, necrotising fasciitis, ecthyma gangrenosum, antiphospholipid syndrome, hypergammaglobulinemia, and cryoglobulinemia. This review serves to increase recognition of these serious pathologies and complications, allowing for prompt diagnosis and swift limb- or life-saving management.
McKennaJKLeifermanKM.Dermatologic drug reactions. Immunol Allergy Clin North Am. 2004;24(3):399-423, vi.
2.
LazarouJPomeranzBHCoreyPN.Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200-1205.
3.
Ad-ElDDMeirovitzAWeinbergAet al. Warfarin skin necrosis: local and systemic factors. Br J Plast Surg. 2000;53(7):624-626.
HarenbergJHoffmannUHuhleGWinklerMBayerlC.Cutaneous reactions to anticoagulants: recognition and management. Am J Clin Dermatol. 2001;2(2):69-75.
6.
GrenierNChen-TsaiC.Nonpalpable purpura within a setting of anticoagulant therapy and metastatic carcinoma. Int J Low Extrem Wounds. 2006;5(3):200-203.
7.
EbyCS.Warfarin-induced skin necrosis. Hematol Oncol Clin North Am. 1993;7(6):1291-1300.
8.
BroekmansAWBertinaRMLoeligerEAHofmannVKlingemannHG.Protein C and the development of skin necrosis during anticoagulant therapy. Thromb Haemost. 1983;49(3):251.
9.
RoujeauJCSternRS.Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331(19):1272-1285.
10.
BrooksLWJrBlaisFX.Coumarin-induced skin necrosis. J Am Osteopath Assoc. 1991;91(6):601-605.
11.
JorgIFenyvesiTHarenbergJ.Anticoagulant-related skin reactions. Expert Opin Drug Saf. 2002;1(3):287-294.
12.
NazarianRMVan CottEMZembowiczADuncanLM.Warfarin-induced skin necrosis. J Am Acad Dermatol. 2009;61(2):325-332.
13.
MiuraYArdenghyMRamasastrySKovachRHochbergJ.Coumadin necrosis of the skin: report of four patients. Ann Plast Surg. 1996;37(3):332-337.
14.
Valeyrie-AllanoreLSassolasBRoujeauJC.Drug-induced skin, nail and hair disorders. Drug Saf. 2007;30(11):1011-1030.
15.
JillellaAPLutcherCL.Reinstituting warfarin in patients who develop warfarin skin necrosis. Am J Hematol. 1996;52(2):117-119.
16.
StewartAJPenmanIDCookMKLudlamCA.Warfarin-induced skin necrosis. Postgrad Med J. 1999;75(882):233-235.
17.
DouketisJDCrowtherMAJulianJAet al. The effects of low-intensity warfarin on coagulation activation in patients with antiphospholipid antibodies and systemic lupus erythematosus. Thromb Haemost. 1999;82(3):1028-1032.
18.
WarkentinTERobertsRSHirshJKeltonJG.Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest. 2005;127(5):1857-1861.
19.
KatsourakisANoussiosGKapoutsisGChatzitheoklitosE.Low molecular weight heparin-induced skin necrosis: a case report. Case Rep Med. 2011;2011:857391.
20.
WarkentinTE.Heparin-induced thrombocytopenia: a clinicopathologic syndrome. Thromb Haemost. 1999;82(2):439-447.
21.
TollAGallardoFAbellaMEFontcubertaJBarrancoCPujolRM.Low-molecular-weight heparin-induced skin necrosis: a potential association with pre-existent hypercoagulable states. Int J Dermatol. 2005;44(11):964-966.
22.
GibsonGEGibsonLEDrageLAGarrettCRGertzMA.Skin necrosis secondary to low-molecular weight heparin in a patient with antiphospholipid antibody syndrome. J Am Acad Dermatol. 1997;37(5, pt 2):855-859.
23.
WutschertRPilettaPBounameauxH.Adverse skin reactions to low molecular weight heparins: frequency, management and prevention. Drug Saf. 1999;20(6):515-525.
24.
SrinivasanAFRiceLBartholomewJRet al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med. 2004;164(1):66-70.
25.
GodetTPerbetSLebretonAet al. Low molecular weight heparin induced skin necrosis without platelet fall revealing immunoallergic heparin induced thrombocytopenia. Case Rep Hematol. 2013;2013:849168.
26.
LevineLEBernsteinJESoltaniKMedenicaMMYungCW.Heparin-induced cutaneous necrosis unrelated to injection sites: a sign of potentially lethal complications. Arch Dermatol. 1983;119(5):400-403.
27.
PlatellCFTanEG.Hypersensitivity reactions to heparin: delayed onset thrombocytopenia and necrotizing skin lesions. Aust N Z J Surg. 1986;56(8):621-623.
28.
NigwekarSUKroshinskyDNazarianRMet al. Calciphylaxis: risk factors, diagnosis, and treatment. Am J Kidney Dis. 2015;66(1):133-146.
29.
NigwekarSUWolfMSternsRHHixJK.Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol. 2008;3(4):1139-1143.
30.
GiachelliCM.Vascular calcification mechanisms. J Am Soc Nephrol. 2004;15(12):2959-2964.
31.
El-AzharyRAPatzeltMTMcBaneRDet al. Calciphylaxis: a disease of pannicular thrombosis. Mayo Clin Proc. 2016;91(10):1395-1402.
32.
WilmerWAMagroCM.Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial. 2002;15(3):172-186.
OzbalkanZCalguneriMOnatAMOzturkMA.Development of calciphylaxis after long-term steroid and methotroxate use in a patient with rheumatoid arthritis. Intern Med. 2005;44(11):1178-1181.
39.
WollinaU.Update on cutaneous calciphylaxis. Indian J Dermatol. 2013;58(2):87-92.
40.
LalGNowellAGLiaoJSuggSLWeigelRJHoweJR.Determinants of survival in patients with calciphylaxis: a multivariate analysis. Surgery. 2009;146(6):1028-1034.
41.
AhronowitzIHarpJShinkaiK.Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol. 2012;13(3):191-211.
42.
BhatRM.Pyoderma gangrenosum: an update. Indian Dermatol Online J. 2012;3(1):7-13.
PowellFCPerryHO.Pyoderma gangrenosum in childhood. Arch Dermatol. 1984;120(6):757-761.
49.
SuWPDavisMDWeenigRHPowellFCPerryHO.Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol. 2004;43(11):790-800.
50.
BrooklynTDunnillGProbertC.Diagnosis and treatment of pyoderma gangrenosum. BMJ. 2006;333(7560):181-184.
51.
WeenigRHDavisMDDahlPRSuWP.Skin ulcers misdiagnosed as pyoderma gangrenosum. N Engl J Med. 2002;347(18):1412-1418.
52.
WuXRShenB.Diagnosis and management of parastomal pyoderma gangrenosum. Gastroenterol Rep (Oxf). 2013;1(1):1-8.
53.
FunabikiKMasuokaHShimizuHet al. Cholesterol crystal embolization (CCE) after cardiac catheterization: a case report and a review of 36 cases in the Japanese literature. Jpn Heart J. 2003;44(5):767-774.
54.
BashoreTMGehrigT.Cholesterol emboli after invasive cardiac procedures. J Am Coll Cardiol. 2003;42(2):217-218.
55.
FukumotoYTsutsuiHTsuchihashiMMasumotoATakeshitaA.Cholesterol Embolism Study I. The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study. J Am Coll Cardiol. 2003;42(2):211-216.
56.
HabibG.Embolic risk in subacute bacterial endocarditis: determinants and role of transesophageal echocardiography. Curr Cardiol Rep. 2003;5(2):129-136.
57.
HittiWAWaliRKWeinmanEJDrachenbergCBrigliaA.Cholesterol embolization syndrome induced by thrombolytic therapy. Am J Cardiovasc Drugs. 2008;8(1):27-34.
58.
GarciaDAKhamashtaMACrowtherMA.How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review. Blood. 2007;110(9):3122-3127.
59.
CrowtherMAWisloffF.Evidence based treatment of the antiphospholipid syndrome II: optimal anticoagulant therapy for thrombosis. Thromb Res. 2005;115(1-2):3-8.
60.
DarmstadtGL.Acute infectious purpura fulminans: pathogenesis and medical management. Pediatr Dermatol. 1998;15(3):169-183.
61.
TalwarAKumarSGopalMGNandiniAS.Spectrum of purpura fulminans: report of three classical prototypes and review of management strategies. Indian J Dermatol Venereol Leprol. 2012;78(2):228.
62.
BetrosianAPBerletTAgarwalB.Purpura fulminans in sepsis. Am J Med Sci. 2006;332(6):339-345.
UrbaniakJRO’NeilMTMeyerLC.Purpura fulminans. J Bone Joint Surg Am. 1973;55(1):69-77.
65.
PriceVELedinghamDLKrumpelAChanAK.Diagnosis and management of neonatal purpura fulminans. Semin Fetal Neonatal Med. 2011;16(6):318-322.
66.
WarnerPMKaganRJYakuboffKPet al. Current management of purpura fulminans: a multicenter study. J Burn Care Rehabil. 2003;24(3):119-126.
67.
AndersenRJCampoliJJoharSKSchumacherKAAllisonEJJr.Suspected brown recluse envenomation: a case report and review of different treatment modalities. J Emerg Med. 2011;41(2):e31-e37.
68.
VetterRS.Seasonality of brown recluse spiders, Loxosceles reclusa, submitted by the general public: implications for physicians regarding loxoscelism diagnoses. Toxicon. 2011;58(8):623-625.
69.
Sanchez-OlivasMAValencia-ZavalaMPSanchez-OlivasJASepulveda-VelazquezGVega-RobledoG.Cutaneous necrotic loxoscelism: a case report [in Spanish]. Rev Alerg Mex. 2011;58(3):171-176.
70.
O’BrienJSSampsonEL.Lipid composition of the normal human brain: gray matter, white matter, and myelin. J Lipid Res. 1965;6(4):537-544.
71.
Guillen-ParedesMPMartinez-FernandezJMorales-GonzalezAPardo-GarciaJL.Septic limb necrosis, secondary to a brown recluse spider bite. Cir Esp. 2016;94(1):e13-e15.
72.
RaderRKStoeckerWVMaltersJMMarrMTDyerJA.Seasonality of brown recluse populations is reflected by numbers of brown recluse envenomations. Toxicon. 2012;60(1):1-3.
73.
VetterRSBushSP.Reports of presumptive brown recluse spider bites reinforce improbable diagnosis in regions of North America where the spider is not endemic. Clin Infect Dis. 2002;35(4):442-445.
74.
ElstonDMEggersJSSchmidtWEet al. Histological findings after brown recluse spider envenomation. Am J Dermatopathol. 2000;22(3):242-246.
75.
YiXAuBuchonJZeltwangerSKirbyJP.Necrotic arachnidism and intractable pain from recluse spider bites treated with lumbar sympathetic block: a case report and review of literature. Clin J Pain. 2011;27(5):457-460.
76.
SteerACLamagniTCurtisNCarapetisJR.Invasive group a streptococcal disease: epidemiology, pathogenesis and management. Drugs. 2012;72(9):1213-1227.
77.
GiulianoALewisFJrHadleyKBlaisdellFW.Bacteriology of necrotizing fasciitis. Am J Surg. 1977;134(1):52-57.
78.
WallDBde VirgilioCBlackSKleinSR.Objective criteria may assist in distinguishing necrotizing fasciitis from nonnecrotizing soft tissue infection. Am J Surg. 2000;179(1):17-21.
79.
KaulRMcGeerALowDEGreenKSchwartzB.Population-based surveillance for group A streptococcal necrotizing fasciitis: clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario Group A Streptococcal Study. Am J Med. 1997;103(1):18-24.
80.
DahlPRPerniciaroCHolmkvistKAO’ConnorMIGibsonLE.Fulminant group A streptococcal necrotizing fasciitis: clinical and pathologic findings in 7 patients. J Am Acad Dermatol. 2002;47(4):489-492.
81.
WardRGWalshMS.Necrotizing fasciitis: 10 years’ experience in a district general hospital. Br J Surg. 1991;78(4):488-489.
82.
ChelsomJHalstensenAHagaTHoibyEA.Necrotising fasciitis due to group A streptococci in western Norway: incidence and clinical features. Lancet. 1994;344(8930):1111-1115.
83.
RojeZRojeZMaticDLibrenjakDDokuzovicSVarvodicJ.Necrotizing fasciitis: literature review of contemporary strategies for diagnosing and management with three case reports: torso, abdominal wall, upper and lower limbs. World J Emerg Surg. 2011;6(1):46.
84.
OliverJD.Wound infections caused by Vibrio vulnificus and other marine bacteria. Epidemiol Infect. 2005;133(3):383-391.
85.
HorsemanMASuraniS.A comprehensive review of Vibrio vulnificus: an important cause of severe sepsis and skin and soft-tissue infection. Int J Infect Dis. 2011;15(3):e157-e166.
86.
TsaiYHHuangTJHsuRWet al. Necrotizing soft-tissue infections and primary sepsis caused by Vibrio vulnificus and Vibrio cholerae non-O1. J Trauma. 2009;66(3):899-905.
87.
KuoYLShiehSJChiuHYLeeJW.Necrotizing fasciitis caused by Vibrio vulnificus: epidemiology, clinical findings, treatment and prevention. Eur J Clin Microbiol Infect Dis. 2007;26(11):785-792.
88.
BrossMHSochKMoralesRMitchellRB.Vibrio vulnificus infection: diagnosis and treatment. Am Fam Physician. 2007;76(4):539-544.
89.
MajeskiJMajeskiE.Necrotizing fasciitis: improved survival with early recognition by tissue biopsy and aggressive surgical treatment. South Med J. 1997;90(11):1065-1068.
90.
BettensSDelaereBGlupczynskiYSchoevaerdtsDSwineC.Ecthyma gangrenosum in a non-neutropaenic, elderly patient: case report and review of the literature. Acta Clin Belg. 2008;63(6):394-397.
91.
KhalilBABaillieCTKennySEet al. Surgical strategies in the management of ecthyma gangrenosum in paediatric oncology patients. Pediatr Surg Int. 2008;24(7):793-797.
92.
BoisseauAMSarlangueJPerelYHehunstreJPTaiebAMalevilleJ.Perineal ecthyma gangrenosum in infancy and early childhood: septicemic and nonsepticemic forms. J Am Acad Dermatol. 1992;27(3):415-418.
GreeneSLSuWPMullerSA.Ecthyma gangrenosum: report of clinical, histopathologic, and bacteriologic aspects of eight cases. J Am Acad Dermatol. 1984;11(5, pt 1):781-787.
95.
HuminerDSiegman-IgraYMorduchowiczGPitlikSD.Ecthyma gangrenosum without bacteremia: report of six cases and review of the literature. Arch Intern Med. 1987;147(2):299-301.
96.
DiFrancescoLMBurkartPHoehnJG.A cutaneous manifestation of antiphospholipid antibody syndrome. Ann Plast Surg. 2003;51(5):517-522.
97.
FrancesC.Dermatological manifestations of Hughes’ antiphospholipid antibody syndrome. Lupus. 2010;19(9):1071-1077.
98.
WeinsteinSPietteW.Cutaneous manifestations of antiphospholipid antibody syndrome. Hematol Oncol Clin North Am. 2008;22(1):67-77, vi.
99.
SharkeyMPDaryananiIIGillettMBJonesSK.Localized cutaneous necrosis associated with the antiphospholipid syndrome. Australas J Dermatol. 2002;43(3):218-220.
100.
MeroniPLBorghiMORaschiETedescoF.Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol. 2011;7(6):330-339.
101.
AshersonRAPietteJC.The catastrophic antiphospholipid syndrome 1996: acute multi-organ failure associated with antiphospholipid antibodies: a review of 31 patients. Lupus. 1996;5(5):414-417.
102.
DengSShenJNiJGongYZhuH.Cutaneous gangrene of the arms and legs after cardiopulmonary resuscitation: a rare presentation of catastrophic antiphospholipid syndrome. Am J Emerg Med. 2017;35(1):191.e3-191.e5.
103.
CreamerDHuntBJBlackMM.Widespread cutaneous necrosis occurring in association with the antiphospholipid syndrome: a report of two cases. Br J Dermatol. 2000;142(6):1199-1203.
104.
StojanovichLMarisavljevicDRovenskyJDjokovichAKozakovaDMilinicN.Clinical and laboratory features of the catastrophic antiphospholipid syndrome. Clin Rev Allergy Immunol. 2009;36(2-3):74-79.
105.
RossiniJRoveranoSGrafCPairaS.Widespread cutaneous necrosis associated with antiphospholipid antibodies: report of four cases. J Clin Rheumatol. 2002;8(6):326-331.
106.
TrejoORamos-CasalsMGarcia-CarrascoMet al. Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore). 2001;80(4):252-262.
107.
LipskerD.Monoclonal gammopathy of cutaneous significance: review of a relevant concept. J Eur Acad Dermatol Venereol. 2017;31(1):45-52.
FriedIArtlMCotaCet al. Clinicopathologic and molecular features in cutaneous extranodal natural killer-/T-cell lymphoma, nasal type, with aggressive and indolent course. J Am Acad Dermatol. 2014;70(4):716-723.
111.
GuitartJWeisenburgerDDSubtilAet al. Cutaneous gammadelta T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas. Am J Surg Pathol. 2012;36(11):1656-1665.
112.
VegaFMedeirosLJGaulardP.Hepatosplenic and other gammadelta T-cell lymphomas. Am J Clin Pathol. 2007;127(6):869-880.
113.
Sokolowska-WojdyloMOlek-HrabKRuckemann-DziurdzinskaK.Primary cutaneous lymphomas: diagnosis and treatment. Postepy Dermatol Alergol. 2015;32(5):368-383.
